Organization
Sichuan Kelun-Biotech Biopharmaceutical
6 clinical trials
3 abstracts
Clinical trial
A Randomized, Open-Label, Multicenter Phase 3 Study of SKB264 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Randomized, Controlled, Open-label, Multi-center Phase III Clinical Trial of SKB264 for Injection Versus Investigator Selected Regimens in Patients With Unresectable Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Who Have Failed Second-line or Above Prior Standard of CareStatus: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
A Phase 2 Clinical Study To Evaluate the Efficacy and Safety of KL-A167 Injection in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Status: Completed, Estimated PCD: 2021-07-13
Clinical trial
A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic TherapyStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2020-08-22
Abstract
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.Org: Guangdong Lung Cancer Institute, Southern Medical University, First Affiliated Hospital of Zhengzhou University, Shanxi Cancer Hospital, The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.Org: Sun Yat-sen University Cancer Center, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Jilin Cancer Hospital, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine,
Abstract
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.Org: Sichuan Kelun-Biotech Biopharmaceutical, Collaborative Innovation Center for Cancer Medicine, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,